Overview
Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
Status:
Completed
Completed
Trial end date:
2008-01-07
2008-01-07
Target enrollment:
0
0
Participant gender:
All
All
Summary
A Phase II trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Paratek Pharmaceuticals IncTreatments:
Linezolid
Criteria
Inclusion Criteria:1. Patients, ages 18 years to 80 years
2. Has an acute complicated skin and skin structure infection
3. Female patients must not be pregnant at the time of enrollment and must agree to a
reliable method of birth control during the study and for 30 days following the last
dose of study drug
Exclusion Criteria:
1. Has received an investigational drug within past 1 month
2. Has been previously enrolled in this protocol
3. Has received >48 hr of a potentially effective systemic antibiotic immediately prior
to study drug
4. Is nursing